Hanna Kaduszkiewicz1, Michael M Kochen, Stefan Kluge, Jakob J Malin, Stephanie Weibel, Nicole Skoetz. 1. Institute of General Medicine, Christian Albrechts University of Kiel; Emeritus, University Medical Center Göttingen; Institute of General Medicine, Faculty of Medicine, University Medical Center Freiburg; Department of Intensive Care Medicine, Hamburg-Eppendorf University Hospital; Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne; Medical Clinic and Polyclinic for Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, University Hospital of Würzburg; Department I of Internal Medicine, Evidence-Based Oncology, Faculty of Medicine and University Hospital of Cologne, University of Cologne; *See eBox for members of the guideline group and the consensus conference (collaborators).
Abstract
BACKGROUND: One of the purposes of outpatient treatment for COVID-19 patients is to prevent severe disease courses and hospitalization. There is a need for evidence-based recommendations to be applied in primary care and specialized outpatient settings. METHODS: This guideline was developed on the basis of publications that were retrieved by a systematic search for randomized controlled trials in the Cochrane COVID-19 trial registry. The quality of evidence was assessed with GRADE, and structured consensus generation was carried out with MAGICapp. RESULTS: Unvaccinated COVID-19 outpatients with at least one risk factor for a severe disease course may be treated in the early phase of the disease with sotrovimab, remdesivir, or nirmatrelvir/ritonavir. Molnupiravir may also be used for such patients if no other clinically appropriate treatment options are available. Immunosuppressed persons with COVID-19 who are at high risk, and whose response to vaccination is expected to be reduced, ought to be treated with sotrovimab. It should be noted, however, that the clinical efficacy of sotrovimab against infections with the omicron subtype BA.2 is uncertain at the currently used dose, as the drug has displayed reduced activity against this subtype in vitro. COVID-19 patients at risk of a severe course may be offered budesonide inhalation, according to an off-label recommendation of the German College of General Practitioners and Family Physicians (other medical societies do not recommend either for or against this treatment). Thrombo - embolism prophylaxis with low-molecular-weight heparin may be given to elderly patients or those with a pre-existing illness. No recommendation is made concerning fluvoxamine or colchicine. Acetylsalicylic acid, azithromycin, ivermectin, systemic steroids, and vitamin D should not be used for the outpatient treatment of COVID-19. CONCLUSION: Drug treatment is now available for outpatients with COVID-19 in the early phase. Nearly all of the relevant trials have been conducted in unvaccinated subjects; this needs to be kept in mind in patient selection.
BACKGROUND: One of the purposes of outpatient treatment for COVID-19 patients is to prevent severe disease courses and hospitalization. There is a need for evidence-based recommendations to be applied in primary care and specialized outpatient settings. METHODS: This guideline was developed on the basis of publications that were retrieved by a systematic search for randomized controlled trials in the Cochrane COVID-19 trial registry. The quality of evidence was assessed with GRADE, and structured consensus generation was carried out with MAGICapp. RESULTS: Unvaccinated COVID-19 outpatients with at least one risk factor for a severe disease course may be treated in the early phase of the disease with sotrovimab, remdesivir, or nirmatrelvir/ritonavir. Molnupiravir may also be used for such patients if no other clinically appropriate treatment options are available. Immunosuppressed persons with COVID-19 who are at high risk, and whose response to vaccination is expected to be reduced, ought to be treated with sotrovimab. It should be noted, however, that the clinical efficacy of sotrovimab against infections with the omicron subtype BA.2 is uncertain at the currently used dose, as the drug has displayed reduced activity against this subtype in vitro. COVID-19 patients at risk of a severe course may be offered budesonide inhalation, according to an off-label recommendation of the German College of General Practitioners and Family Physicians (other medical societies do not recommend either for or against this treatment). Thrombo - embolism prophylaxis with low-molecular-weight heparin may be given to elderly patients or those with a pre-existing illness. No recommendation is made concerning fluvoxamine or colchicine. Acetylsalicylic acid, azithromycin, ivermectin, systemic steroids, and vitamin D should not be used for the outpatient treatment of COVID-19. CONCLUSION: Drug treatment is now available for outpatients with COVID-19 in the early phase. Nearly all of the relevant trials have been conducted in unvaccinated subjects; this needs to be kept in mind in patient selection.
Authors: Brian M Clemency; Renoj Varughese; Yaneicy Gonzalez-Rojas; Caryn G Morse; Wanda Phipatanakul; David J Koster; Michael S Blaiss Journal: JAMA Intern Med Date: 2022-01-01 Impact factor: 21.873
Authors: Anil Gupta; Yaneicy Gonzalez-Rojas; Erick Juarez; Manuel Crespo Casal; Jaynier Moya; Diego R Falci; Elias Sarkis; Joel Solis; Hanzhe Zheng; Nicola Scott; Andrea L Cathcart; Christy M Hebner; Jennifer Sager; Erik Mogalian; Craig Tipple; Amanda Peppercorn; Elizabeth Alexander; Phillip S Pang; Almena Free; Cynthia Brinson; Melissa Aldinger; Adrienne E Shapiro Journal: N Engl J Med Date: 2021-10-27 Impact factor: 91.245
Authors: Saye H Khoo; Richard Fitzgerald; Thomas Fletcher; Sean Ewings; Thomas Jaki; Rebecca Lyon; Nichola Downs; Lauren Walker; Olana Tansley-Hancock; William Greenhalf; Christie Woods; Helen Reynolds; Ellice Marwood; Pavel Mozgunov; Emily Adams; Katie Bullock; Wayne Holman; Marcin D Bula; Jennifer L Gibney; Geoffrey Saunders; Andrea Corkhill; Colin Hale; Kerensa Thorne; Justin Chiong; Susannah Condie; Henry Pertinez; Wendy Painter; Emma Wrixon; Lucy Johnson; Sara Yeats; Kim Mallard; Mike Radford; Keira Fines; Victoria Shaw; Andrew Owen; David G Lalloo; Michael Jacobs; Gareth Griffiths Journal: J Antimicrob Chemother Date: 2021-11-12 Impact factor: 5.758
Authors: David J Sullivan; Kelly A Gebo; Shmuel Shoham; Evan M Bloch; Bryan Lau; Aarthi G Shenoy; Giselle S Mosnaim; Thomas J Gniadek; Yuriko Fukuta; Bela Patel; Sonya L Heath; Adam C Levine; Barry R Meisenberg; Emily S Spivak; Shweta Anjan; Moises A Huaman; Janis E Blair; Judith S Currier; James H Paxton; Jonathan M Gerber; Joann R Petrini; Patrick B Broderick; William Rausch; Marie-Elena Cordisco; Jean Hammel; Benjamin Greenblatt; Valerie C Cluzet; Daniel Cruser; Kevin Oei; Matthew Abinante; Laura L Hammitt; Catherine G Sutcliffe; Donald N Forthal; Martin S Zand; Edward R Cachay; Jay S Raval; Seble G Kassaye; E Colin Foster; Michael Roth; Christi E Marshall; Anusha Yarava; Karen Lane; Nichol A McBee; Amy L Gawad; Nicky Karlen; Atika Singh; Daniel E Ford; Douglas A Jabs; Lawrence J Appel; David M Shade; Stephan Ehrhardt; Sheriza N Baksh; Oliver Laeyendecker; Andrew Pekosz; Sabra L Klein; Arturo Casadevall; Aaron A R Tobian; Daniel F Hanley Journal: N Engl J Med Date: 2022-03-30 Impact factor: 176.079
Authors: Sanjay Ramakrishnan; Dan V Nicolau; Beverly Langford; Mahdi Mahdi; Helen Jeffers; Christine Mwasuku; Karolina Krassowska; Robin Fox; Ian Binnian; Victoria Glover; Stephen Bright; Christopher Butler; Jennifer L Cane; Andreas Halner; Philippa C Matthews; Louise E Donnelly; Jodie L Simpson; Jonathan R Baker; Nabil T Fadai; Stefan Peterson; Thomas Bengtsson; Peter J Barnes; Richard E K Russell; Mona Bafadhel Journal: Lancet Respir Med Date: 2021-04-09 Impact factor: 30.700
Authors: Robert L Gottlieb; Carlos E Vaca; Roger Paredes; Jorge Mera; Brandon J Webb; Gilberto Perez; Godson Oguchi; Pablo Ryan; Bibi U Nielsen; Michael Brown; Ausberto Hidalgo; Yessica Sachdeva; Shilpi Mittal; Olayemi Osiyemi; Jacek Skarbinski; Kavita Juneja; Robert H Hyland; Anu Osinusi; Shuguang Chen; Gregory Camus; Mazin Abdelghany; Santosh Davies; Nicole Behenna-Renton; Frank Duff; Francisco M Marty; Morgan J Katz; Adit A Ginde; Samuel M Brown; Joshua T Schiffer; Joshua A Hill Journal: N Engl J Med Date: 2021-12-22 Impact factor: 91.245
Authors: Markus Hoffmann; Nadine Krüger; Sebastian Schulz; Anne Cossmann; Cheila Rocha; Amy Kempf; Inga Nehlmeier; Luise Graichen; Anna-Sophie Moldenhauer; Martin S Winkler; Martin Lier; Alexandra Dopfer-Jablonka; Hans-Martin Jäck; Georg M N Behrens; Stefan Pöhlmann Journal: Cell Date: 2021-12-24 Impact factor: 41.582
Authors: Ly-Mee Yu; Mona Bafadhel; Jienchi Dorward; Gail Hayward; Benjamin R Saville; Oghenekome Gbinigie; Oliver Van Hecke; Emma Ogburn; Philip H Evans; Nicholas P B Thomas; Mahendra G Patel; Duncan Richards; Nicholas Berry; Michelle A Detry; Christina Saunders; Mark Fitzgerald; Victoria Harris; Milensu Shanyinde; Simon de Lusignan; Monique I Andersson; Peter J Barnes; Richard E K Russell; Dan V Nicolau; Sanjay Ramakrishnan; F D Richard Hobbs; Christopher C Butler Journal: Lancet Date: 2021-08-10 Impact factor: 79.321